Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a protein called Annexin A2 (ANXA2) and its role in a condition known as Antiphospholipid Syndrome (APS). APS can lead to blood clots and other serious complications. Researchers want to see how much ANXA2 is present on certain immune cells in patients with APS. Understanding this could help explain some of the problems related to APS and potentially lead to better treatments.

To participate in the trial, you must be an adult (18 years or older) diagnosed with APS according to specific medical guidelines. Unfortunately, people with certain other health issues, such as cancers or other autoimmune diseases, cannot join. If you are eligible and decide to participate, you can expect to have your blood tested to measure the levels of ANXA2 on your immune cells. This research is important because it may reveal new ways that APS affects the body, which could eventually help improve care for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • APS patients who fulfilled the revised criteria for APS
• Exclusion Criteria:
• • Patients less than 18 years old
• • Solid and hematological malignancies
• • Other autoimmune diseases
• • Cirrhosis